Similarly, the consequence of downregulating PRMT6 activity in cancer cells, and the identification of relevant downstream targets, with the exception of the inhibitor of cell migration thrombospondin 1 (22), has not been fully elucidated, hampering its potential exploitation as a drug target in oncology. Here, PRMT6 is linked to cancer.